Is gastrectomy indicated? A study recently published in JAMA suggests lower lifetime gastric cancer risk for CDH1 mutation carriers. Will this lead to changes in management recommendations?

“Less Radical” podcast: Resistance to change, a data scandal

“Less Radical” is the story of Bernie Fisher, the surgeon-scientist who not only revolutionized breast cancer treatment, but also fundamentally changed the way we understand all cancers.

November 01, 2024

Vol.50 No.41

Drugs & Targets

FDA approves Vyloy+chemo for gastric or GEJ junction adenocarcinoma with CLDN18.2-positive tumors

FDA has approved Vyloy (zolbetuximab-clzb), a claudin 18.2-directed cytolytic antibody, with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are CLDN18.2 positive, as determined by an FDA-approved test.

October 25, 2024

Vol.50 No.40

Clinical

Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer

If clinical research were anything like fly fishing, the scientific question that EA3163 trial attempted to answer might be considered “the one that got away”.

Less Radical podcast: The origins of modern surgery, radical mastectomy, and the first randomized trials in breast cancer

Less Radical tells the story of surgeon-scientist Bernie Fisher, who revolutionized breast cancer treatment and transformed the way we understand cancer.

October 11, 2024

Vol.50 No.38

In Brief

Jane Figueiredo appointed co-leader of Cancer Prevention and Control Program at Cedars-Sinai

Jane Figueiredo was appointed co-leader of the Cancer Prevention and Control Program at Cedars-Sinai Cancer Center.

October 11, 2024

Vol.50 No.38

Regulatory News

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitors
Vote may lead to rollback of some indications held by BMS and Merck

The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated as a first-line treatment for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.

October 04, 2024

Vol.50 No.37

By Jacquelyn Cobb

Is gastrectomy indicated?

A study recently published in JAMA suggests lower lifetime gastric cancer risk for CDH1 mutation carriers. Will this lead to changes in management recommendations?

YOU MAY BE INTERESTED IN

“Less Radical” podcast: Resistance to change, a data scandal

FDA approves Vyloy+chemo for gastric or GEJ junction adenocarcinoma with CLDN18.2-positive tumors

Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer

Less Radical podcast: The origins of modern surgery, radical mastectomy, and the first randomized trials in breast cancer

Jane Figueiredo appointed co-leader of Cancer Prevention and Control Program at Cedars-Sinai

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitors
Vote may lead to rollback of some indications held by BMS and Merck

Renew today!

Subscriber content

Login

Is gastrectomy indicated?

A study recently published in JAMA suggests lower lifetime gastric cancer risk for CDH1 mutation carriers. Will this lead to changes in management recommendations?

YOU MAY BE INTERESTED IN

“Less Radical” podcast: Resistance to change, a data scandal

FDA approves Vyloy+chemo for gastric or GEJ junction adenocarcinoma with CLDN18.2-positive tumors

Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer

Less Radical podcast: The origins of modern surgery, radical mastectomy, and the first randomized trials in breast cancer

Jane Figueiredo appointed co-leader of Cancer Prevention and Control Program at Cedars-Sinai

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitorsVote may lead to rollback of some indications held by BMS and Merck

Login

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitors
Vote may lead to rollback of some indications held by BMS and Merck